LENZ Therapeutics, Inc. financial data

Symbol
GRPH on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
445 Marine View Ave Suite 320, Del Mar, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Graphite Bio, Inc. (to 3/19/2024)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24K % -43.7%
Debt-to-equity 30.7 % +96%
Return On Equity -96.4 % -62.9%
Return On Assets -61.2 % -130%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.5M shares -56.1%
Common Stock, Shares, Outstanding 25.5M shares -56.2%
Entity Public Float 151M USD +0.47%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 4.72M shares +142%
Weighted Average Number of Shares Outstanding, Diluted 4.72M shares +142%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 32.3M USD -50.1%
General and Administrative Expense 41M USD +24.7%
Operating Income (Loss) -139M USD -50.2%
Nonoperating Income (Expense) 10M USD +128%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -129M USD -46.4%
Earnings Per Share, Basic 0.78 USD/shares +45.7%
Earnings Per Share, Diluted 0.78 USD/shares +45.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 200M USD +187%
Cash, Cash Equivalents, and Short-term Investments 213M USD +80764762%
Assets, Current 217M USD -19.8%
Property, Plant and Equipment, Net 49K USD -99.9%
Operating Lease, Right-of-Use Asset 578K USD -85.6%
Other Assets, Noncurrent 0 USD -100%
Assets 217M USD -29.9%
Accounts Payable, Current 7.13M USD +258%
Employee-related Liabilities, Current 816K USD -37.9%
Accrued Liabilities, Current 11.8M USD
Liabilities, Current 18.9M USD +31.7%
Operating Lease, Liability, Noncurrent 156K USD -89%
Other Liabilities, Noncurrent 111K USD
Liabilities 19.2M USD -43.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +99.8%
Retained Earnings (Accumulated Deficit) -112M USD +58%
Stockholders' Equity Attributable to Parent 198M USD
Liabilities and Equity 217M USD -29.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.9M USD -87%
Net Cash Provided by (Used in) Financing Activities 171M USD +106%
Net Cash Provided by (Used in) Investing Activities 18M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 25.5M shares -56.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 165M USD +135%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 200M USD +74.6%
Deferred Tax Assets, Valuation Allowance 67.6M USD +77.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 67.7M USD +72.3%
Operating Lease, Liability 296K USD -93.5%
Depreciation 2.4M USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.7M USD -31.5%
Lessee, Operating Lease, Liability, to be Paid 319K USD -93.4%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 433K USD -86.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 161K USD -57.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 117K USD -92%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 23K USD -91.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 41K USD
Deferred Tax Assets, Operating Loss Carryforwards 30.8M USD +93.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.56M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.49M USD
Operating Lease, Payments 44.1M USD +615%
Additional Paid in Capital 310M USD -42.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 73 USD -93.8%
Share-based Payment Arrangement, Expense 11.4M USD +10.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%